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Connexin hemichannels, which are plasma membrane hexameric channels (connexons)
composed of connexin protein protomers, have been implicated in a host of
physiological processes and pathological conditions. A number of single point
pathological mutations impart a “leaky” character to the affected hemichannels, i.e.,
make them more active or hyperactive, suggesting that normal physiological condition
could be recovered using selective hemichannel inhibitors. Recently, a human-derived
monoclonal antibody named abEC1.1 has been shown to inhibit both wild type and
hyperactive hemichannels composed of human (h) connexin 26 (hCx26) subunits. The
aims of this work were (1) to characterize further the ability of abEC1.1 to selectively
modulate connexin hemichannel function and (2) to assess its in vitro stability in view of
future translational applications. In silico analysis of abEC1.1 interaction with the hCx26
hemichannel identified critically important extracellular domain amino acids that are
conserved in connexin 30 (hCx30) and connexin 32 (hCx32). Patch clamp experiments
performed in HeLa DH cells confirmed the inhibition efficiency of abEC1.1 was
comparable for hCx26, hCx30 and hCx32 hemichannels. Of note, even a single amino
acid difference in the putative binding region reduced drastically the inhibitory effects
of the antibody on all the other tested hemichannels, namely hCx30.2/31.3, hCx30.3,
hCx31, hCx31.1, hCx37, hCx43 and hCx45. Plasma membrane channels composed
of pannexin 1 were not affected by abEC1.1. Finally, size exclusion chromatography
assays showed the antibody does not aggregate appreciably in vitro. Altogether, these
results indicate abEC1.1 is a promising tool for further translational studies.
Keywords: connexin hemichannels, rare diseases, phage display libraries, therapeutic monoclonal antibodies,
molecular dynamics, patch clamp
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INTRODUCTION
Connexins are a family of integral transmembrane proteins
(indicated by Cx followed by their molecular weight in kDa,
e.g., hCx26 for human connexin 26, encoded by the GJB2 gene)
which form hexameric plasma membrane structures known as
“connexons.” A connexon may function as a regular plasma
membrane channel, termed “hemichannel,” or dock head-to head
with another connexon from an opposing cell and self-assemble
into a gap junction intercellular channel (Mammano, 2018).
Partial high-resolution crystal structures have been
determined only for hCx26 (Maeda et al., 2009) and sheep
Cx46/50 (Myers et al., 2018). However, due to the relatively high
sequence similarity across the family, all connexin proteins are
thought to share a topology similar to that of hCx26 or Cx46/50,
which comprise 4 transmembrane helices (TM1-4) connected by
2 extracellular loops (EC1, EC2) and 1 intracellular loop (ICL).
An N-terminal helix (NTH) domain folds into the cytoplasmic
channel vestibule and is connected to the pore-lining TM1
helix via a short linker. The ICL, connecting TM2–TM3, and
the cytoplasmic C-terminal domain (CTD) were not resolved
(Maeda et al., 2009; Myers et al., 2018). The CTD, which is
considered to be unstructured, is the most diverse domain and its
length is different in each connexin isoform. The fairly conserved
sequences of EC1 and EC2 suggest the extracellular vestibule of
all hemichannels has a relatively rigid three-dimensional (3D)
structure. In MD simulations lasting ∼100 ns, it appears to be
the stiffest part of the hemichannel (Zonta et al., 2012) due to the
presence of six conserved cysteine residues, three in each loop,
forming intramolecular disulfide bonds between EC1 and EC2
(Maeda et al., 2009; Myers et al., 2018).
In a hCx26 gap junction channel, the extracellular docking
interface of each connexon comprises hydrogen bonding between
Asn54 of EC1 and the main-chain amide of Leu56 in the
opposite protomer, and a pair of Gln57 in two diagonally
opposite protomers (these residues are highly conserved among
connexins). Also EC2 contributes to the connexon-connexon
interaction with a complex network of hydrogen bonds and salt
bridges mediated by Lys168, Asn176, Thr177 and Asp179 in two
opposite protomers (Maeda et al., 2009).
Accurate control of undocked hemichannel gating is crucial
for cell survival and organism health. Indeed, “leaky” or more
active mutant hemichannels result in cell death when expressed
in model cells (Abrams et al., 2002; Essenfelder et al., 2004; Liang
et al., 2005; Stong et al., 2006; Dobrowolski et al., 2007, 2008;
Abbreviations: 3D, three-dimensional; [Ca2+], calcium ion concentration;
Ca2+, calcium ion; CBX, carbenoxolone, 3β-Hydroxy-11-oxoolean-12-en-30-
oic acid 3-hemisuccinat; CDR, complementarity determining regions; CTD,
C-terminal domain; Cx, connexin; DIC, differential interference contrast; DIDS,
4,4-Diisothiocyanatostilbene-2,2-disulfonic acid; DMEM, Dulbecco’s modified
Eagle’s medium; EC1,2, extracellular loop 1, 2; ECSNaCl, sodium chloride-based
extracellular solution; FBS, fetal bovine serum; Fc, fragment constant; HC, heavy
chain; ICL, intracellular loop; ICSKAsp, potassium aspartate-based intracellular
solution; IgG1, immunoglobulin G1; LC, light chain; MD, molecular dynamics;
NTH, N-terminal helix; OD, optical density; ORF, open reading frame; P1-6,
protomers 1 to 6 of a homomeric hCx26 hemichannel; PBS, phosphate-buffered
saline; ScFv, single chain fragment variable; SEC, size exclusion chromatography;
TEA-Cl, 4 tetraethyl ammonium chloride; TM1-4, transmembrane helix 1 to 4; Wt,
wild type; YFP, yellow fluorescent protein.
Lee and White, 2009; Sanchez et al., 2010, 2013, 2014; Tong et al.,
2011; Yao et al., 2011; Chi et al., 2012; Kozoriz et al., 2013; Mhaske
et al., 2013; Ren et al., 2013; Berger et al., 2014; Patel et al., 2014;
Sun et al., 2014; Zhu et al., 2014; Wang et al., 2015; Sanchez
et al., 2016; Press et al., 2017; Xu et al., 2017; Srinivas et al.,
2019); reviewed in Retamal et al. (2015), Laird and Lampe (2018),
and Srinivas et al. (2018).
Recently, a human-derived single-chain fragment variable
(scFv) fragment constant (Fc) antibody (scFv-Fc) named abEC1.1
(Qu et al., 2017) was shown to inhibit both wild type (wt) and
hyperactive pathological hCx26 hemichannels (Xu et al., 2017).
The crystal structure of the scFv domain was solved (Protein
Data Base accession code 5WYM) and some of the residues that
are critical for its binding to the extracellular domain of hCx26
hemichannels were identified.
The goals of the present study were to characterize further the
biophysical properties of this antibody, particularly its selectivity
for connexin hemichannels, and to assay its in vitro stability,
which is a pre-requisite for future in vivo delivery to animal
models of disease.
MATERIALS AND METHODS
Antibody Production
The gene encoding the antibody scFv domain was cloned into a
pFUSE-Fc expression vector (Cat. No. pfuse-hg1fc2, Invivogen,
Hong Kong) to generate abEC1.1 as a diabody-Fc fusion protein
(Wu et al., 2001) which comprises the entire Fc domain of
human immunoglobulin G1 (IgG1) (Silverton et al., 1977; Bujak
et al., 2014; Frenzel et al., 2016). In addition, the pFUSE-Fc
expression vector was modified to generate a variant of the
antibody with a murine Fc (abEC1.1m). For antibody production,
a FreeStyleTM 293-F cell line (Thermo Fisher Scientific, Cat.
No. R79007), maintained in Freestyle 293 Expression Medium
(Thermo Fisher Scientific, Cat. No. 12338026), was stably
transfected with the abEC1.1 or abEC1.1m expression vector.
Expressed antibodies were purified using HiTrap Protein A
HP columns (GE Healthcare, Cat. No. 17-0403-03) with the
ÄKTApurifier 100 system (GE Healthcare). After purification, the
buffer was exchanged to PBS (pH 7.4) and the antibodies were
kept in PBS at 4◦C.
Size Exclusion Chromatography (SEC)
To characterize the in vitro stability of abEC1.1 and abEC1.1m
by SEC (Fekete et al., 2014; Bobaly et al., 2017), eppendorf tubes
containing 4.2 mg/mL of antibody per tube were incubated at
4◦C, room temperature (∼22◦C), 37◦C and 42◦C for 3, 5, 7
and 16 days. At each time point, 20 µL of solution were loaded
into a Nanofilm SEC-250 column (Sepax Technologies, Inc.,
DW, United States) and processed at flow-rates of 0.5 mL/min
using a 1290 Infinity II liquid chromatography system (Agilent
Technologies, Santa Clara, CA, United States). Raw data
generated by the instrument (optical density, OD, measured at
405 nm vs. retention time) were normalized to the peak of
each chromatogram and plotted using OriginPro 2017 software
(OriginLab, Northampton, MA, United States).
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Construction of Connexin-Venus
Transfection Vectors
The coding regions of wt homo sapience connexin genes1
were synthesized (by Shanghai Sangon Biological Engineering
Technology & Services Co., Ltd.) without stop codon and
subcloned into a pcDNA3.1(+) mammalian expression vector
(Cat. No. V79020, Thermo Fisher Scientific) that had been
previously modified for C-terminal fusion of connexin genes with
Venus, a circularly permuted mutant of the yellow fluorescent
protein (YFP) (Beltramello et al., 2005). After transformation
into Escherichia coli (TOP10, Cat. No. C404010, Thermo Fisher
Scientific), miniplasmid preparation and restriction enzyme
analysis were performed to identify positive clones. To verify
that PCR amplification did not introduce unwanted mutations,
all constructs were sequenced (by Eurofins Genomics S.r.l.,
Milan, Italy) using standard primers complementary to the
plasmid common regions of the constructs, adjacent to the target
open reading frames (ORF). Both orientations were sequenced
when sequencing was insufficiently reliable as a consequence
of the length of the ORF. The primers sequences used for this
purpose were:
T7: 5′-TAATACGACTCATAGGG;
myc-ddk-rev: 5′-TGCCAGATCCTCTTCTGAGATGAG.
Patch Clamp Electrical Measurements
Communication–incompetent HeLa DH cells (Cat. No.
96112022, Sigma-Aldrich/Merck, Milan, Italy) were seeded
onto round glass coverslip (Cat. No. FIS#12-542A, Thermo
Fisher Scientific) and maintained in Dulbecco’s modified Eagle’s
medium (DMEM, Cat. No. 41965039, Thermo Fisher Scientific)
containing 10% (v/v) fetal bovine serum (FBS, Cat. No. 10270-
106, Gibco-Invitrogen) and 1% penicillin/streptomycin (Cat.
No. 15070-063, Gibco-Invitrogen). Twenty four hours after
plating, the Lipofectamine 3000 transfection reagent (Cat. No.
L3000-015, Thermo Fisher Scientific) was used to transiently
transfect HeLa DH cells at 25-30% confluence with one of the
connexin-Venus plasmids.
For patch clamp recordings, a double stage vertical puller
(PP-830, Narishige) or horizontal laser-based puller (P-2000,
Sutter Instrument) were used to fabricate patch pipettes from
glass capillaries (G85150T-4, Harvard Apparatus, Edenbridge,
United Kingdom). Pipettes were filled with a potassium
aspartate-based intracellular solution (ICSKAsp) containing (in
mM): 115 KAsp, 10 NaCl, 10 KCl, 1 MgCl2, 10 HEPES, 1
CaCl2 and 4 BAPTA tetrapotassium salt (pH 7.2, 311 mOsm)
and filtered through 0.22-mm pores (Millipore). Twenty four
hours after transfection, glass coverslips with adherent cells were
transferred to the stage of an upright fluorescence microscope
(BX51, Olympus) equipped with differential interference contrast
(DIC) optics. Cells were continuously superfused at 2 ml/min
at 20–23◦C with a sodium chloride-based extracellular solution
(ECSNaCl) containing a reduced (0.2 mM) Ca2+ concentration
([Ca2+]e) and (in mM): 140 NaCl, 5 KCl, 10 HEPES, 2
sodium pyruvate, 4 tetraethylammonium chloride (TEA-Cl),
1As listed at https://www.ncbi.nlm.nih.gov/nuccore.
1 MgCl2, 4 CsCl and 5 glucose (pH 7.4, 323 mOsm).
Filled patch pipettes had resistances of 4–6 M when
immersed in ECSNaCl.
Hemichannel currents were assayed in ECSNaCl while keeping
cells near their zero-current potential (between −20 and 0 mV)
under whole cell patch clamp recording conditions. Cells were
transiently depolarized to +40 mV for 20 s followed by a
ramp down −40 or −60 mV and subsequently held at this
negative potential for up to 1 min before stepping back to
the zero-current potential. The ramp from positive to negative
potentials was preferred to a step to minimize stress to the
plasma membrane. To estimate plasma membrane leak currents,
connexin hemichannels were blocked by adding either CaCl2
(2 mM) or ZnCl2 (100 µM) to the superfusion medium
(Xu et al., 2017).
For antibody application, the opening of a glass micropipette
connected to a pneumatic pico-pump (PV820, World Precision
Instruments Inc., Sarasota, FL, United States) and filled with
the ECSNaCl extracellular solution supplemented with abEC1.1
(952 nM) was positioned near the patched cell. During antibody
delivery, the superfusion was stopped.
Negative control experiments were performed in HeLa-
Panx1-YFP cells (Yi et al., 2017) grown in DMEM with
10% FBS, containing G418 (Cat. No. 4727878001, Sigma-
Aldrich/Merck) at a final concentration of 1 µg/mL at 37◦C in
an incubator supplemented with 5% CO2. Pannexin currents
were inhibited using the following compounds, all from Sigma-
Aldrich/Merck: p-(Dipropylsulfamoyl)benzoic acid (probenecid,
Cat. No. P-8761), 3β-Hydroxy-11-oxoolean-12-en-30-oic acid
3-hemisuccinate (carbenoxolone, CBX, Cat. No. C4790), 4,4-
Diisothiocyanatostilbene-2,2-disulfonic acid (DIDS, D3514) and
Fast Green FCF (Cat. No. F7252-5G).
Dye Uptake Assay
HeLa DH cells expressing the connexin of interest were
imaged in an upright fluorescence microscope (Bergamo II,
Thorlabs Inc., Thorlabs Inc., Newton, NJ, United States) using
a 25× water immersion objective (XLPLN25XWMP2, 1.05
N.A., Olympus Corporation, Tokyo, Japan) and a programmable
illumination system (pE-4000, CoolLED Ltd., Andover, United
Kingdom) coupled to the epifluorescence port of the microscope
via 474/24 nm bandpass filter (Semrock, Rochester, NY,
United States) and dichroic beamsplitter (410/504/582/669 nm
BrightLine quad-edge, Semrock). Fluorescence emission was
filtered through a 525/39 nm bandpass filter (Semrock) to form
images on the sensor of a scientific CCD camera (1501M-USB-
TE, Thorlabs). HeLa DH transfectants were maintained in a
divalent-free extracellular medium (ECM) containing (in mM):
140 NaCl, 5 KCl, 10 HEPES, 2 sodium pyruvate, and 5 glucose
(pH 7.4). Five non-overlapping fields of view were rapidly imaged
under fixed illumination and recording conditions (time t0)
using a precision programmable motorized stage (HLD117NN,
Prior Scientific Instruments Ltd., Cambridge, United Kingdom).
Thereafter, cells were switched to ECM supplemented with 2 mM
Lucifer Yellow (CH dilithium salt, Sigma-Aldrich/Merck, Cat.
No. L0259) to promote dye uptake (DeVries and Schwartz, 1992;
Saez and Leybaert, 2014). After 30 min of incubation (time t30),
cells were washed three times with ECM supplemented with
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2 mM CaCl2 (ECMCa) in order to remove dye molecules bound
to the outer plasma membrane leaflet and to limit dye escape
from cell cytoplasm through open hemichannels. Thereafter, a
new set of 5 images were rapidly acquired from the same fields
of view. For off-line image processing, regions of interest (ROIs)
were drawn over individual cells and ROI average fluorescence
intensities were computed. To test antibody efficacy, batches
of cells which had been pre-incubated for 30 min in ECM
supplemented with abEC1.1 (952 nM) were imaged as explained
above. Cells transfected with an empty pcDNA3.1(+) vector
(mock transfected) were used as controls for aspecific dye uptake
effects. The distributions of fluorescence values, sampled before
and after Lucifer Yellow application, were compared statistically
using the Mann–Whitney U test (Mann and Whitney, 1947).
Molecular Modeling and Dynamics
The abEC1.1 model was derived by homology from two different
templates, one for the scFv domain and the other for the Fc
domain, which were interconnected by a linker using the Swiss
Model website (Biasini et al., 2014). The scFv domain was then
docked to the extracellular domain of a published model of hCx26
hemichannel embedded in the plasma membrane (Zonta et al.,
2012) using the ClusPro 2.0 server (Comeau et al., 2004), and
the antibody docking mode (Brenke et al., 2012). Among the 50
docking configurations generated by the software, we selected the
only one in which the 3 complementarity determining regions
(CDRs) of the abEC1.1 heavy chain faced the EC1 loop of
hCx26. Configuration stability was tested by performing a MD
simulation using the Gromacs 4 package (Pronk et al., 2013)
and the Amber03 force field (Duan et al., 2003). Specifically,
the atomistic model system, containing the hCx26 hemichannel
inserted in a phospholipid bilayer and the docked antibody,
underwent a short energy minimization in vacuum and was
subsequently solvated with full atom TIP3P water, containing
Cl− and K+ ions at a concentration of ∼0.15 M in order to
mimic a physiological ionic strength. After solvation, the total
number of atoms was around 2.53× 105. We then performed an
equilibrium MD simulation under periodic boundary conditions
at constant pressure for 150 ns and analyzed the last 10 ns after
equilibration. Temperature T and pressure P were kept constant,
at 300 K and 1 atm, respectively, using the Berendsen thermostat
and barostat (Berendsen et al., 1984). Fast smooth Particle–Mesh
Ewald summation (Darden et al., 1993) was used for long–
range electrostatic interactions, with a cut off of 1.0 nm for the
direct interactions.
RESULTS
In silico Analysis of abEC1.1 Interaction
With the Extracellular Domain of the
hCx26 Hemichannel
Starting from the equilibrated configuration of two abEC1.1
antibodies simultaneously docked to a hCx26 hemichannel (Xu
et al., 2017) (Figure 1), we analyzed the last 10 ns of the
MD simulation (see section “Materials and Methods”) and
searched for antibody-connexin residue pairs that interacted
FIGURE 1 | Side view of an antibody pair binding a hCx26 hemichannel.
According to our model and to the experimental determination of the
stoichiometry of binding, two different antibodies can simultaneously bind the
extracellular region of a single connexin hemichannel. Each antibody is a
diabody-Fc, i.e., a dimer of two scFv-Fc polypeptides where the heavy chain
(HC) and light chain (LC) from one scFv, pair with the complementary domains
of a second scFv (Perisic et al., 1994). In the figure, Fc domains are not
shown and each ScFv domain is represented with a different color (green, red,
yellow or purple); green-red and yellow-purple represent the two different
diabodies, while the connexin hemichannel is shown in blue. For additional
structural details, see Xu et al. (2017).
stably. Interaction probability was measured as the fraction of
the simulation time in which the distance between each pair
of residues was less than an arbitrarily pre-assigned threshold
(2 Å). Figure 2 highlights hemichannel residues involved in the
interaction with abEC1.1 according to this scoring method. Based
on this analysis, we concluded that abEC1.1 binds Asn54, Thr55,
Leu56, Gln57, and Pro58 in EC1, as well as Pro175, Asn176 and
Thr177 in EC2. Each antibody appears to interact directly with
four different protomers (P) of the connexon: the first antibody
interacts with P1, P2, P3, and P4; the second with P4, P5, P6, and
P1, thus the pair of diametrically opposed protomers, P1 and P4,
is able to interact with both binding antibodies at the same time.
In other words, the stoichiometry of binding between connexins
and antibodies is 6:2, with the two antibodies binding in a
symmetric configuration relative to the axis of the channel pore.
Details of the interactions are illustrated in Figure 3. Note that
only EC1 residues Asn54, Thr55 and Leu56 were present in the
bait peptide used to select abEC1.1 out of a phage display library
with∼1011 variability (Zhang et al., 2012). Sequence alignment of
all human connexins showed that only hCx26, hCx30 and hCx32
display identical sub-sequences in the predicted binding region
(Table 1). Therefore we reasoned that the antibody should inhibit
also hCx30 and hCx32 hemichannels, whereas it might be less
effective or ineffective when applied to hemichannels formed by
other connexin isoforms.
Experimental Validation of Model
Predictions by Patch Clamp in HeLa
DH Transfectants
To test these hypotheses, we performed a series of experiments
in HeLa DH cells transiently transfected with the cDNAs
Frontiers in Physiology | www.frontiersin.org 4 June 2019 | Volume 10 | Article 392
fphys-10-00392 June 7, 2019 Time: 18:30 # 5
Ziraldo et al. abEC1.1 Specifically Modulates Connexin Hemichannels
FIGURE 2 | hCx26 hemichannel residues predicted to interact with abEC1.1. (A,B) Schematic representation of a hCx26 hemichannel viewed from the extracellular
side. The most important hemichannel residues (percentage of interaction > 55%) interacting with abEC1.1 are highlighted. In panel B, different protomers (P1 to P6)
of the hCx26 hemichannel are shown with different colors; labeled circles represent the position of the alpha carbon of residues shown in panel A; orange and blue
residues represent the binding regions of the two scFv composing each diabody. Four N-T-L motifs are inscribed in an ellipse to indicate interaction of the
corresponding hemichannel residues with either one (for P2 and P5) or both (for P1 and P4) binding diabodies. (C,D) Positions of all single protomer residues
potentially involved in the interaction with the hemichannel (C, top view; D, side view); the EC1 loop is represented in red, the EC2 loop in light blue.
encoding selected human connexins tagged with the Venus
fluorescent protein at their C-terminus (see section “Materials
and Methods”). The analysis was carried out on HeLa DH
transfectants that generated reliable responses to a previously
tested voltage clamp protocol (Xu et al., 2017) designed to
elicit hemichannel currents upon depolarization followed by tail
currents upon hyperpolarization.
In cells expressing hCx30 (encoded by GJB6) and hCx32
(GJB1), whole cell current recordings showed a major reduction
of the elicited currents in the presence of the antibody (952
nM; Figures 4A,B). Incubating hCx30 or hCx32 HeLa DH
transfectants in Ca2+-free extracellular medium containing
Lucifer Yellow (1 mM) promoted dye uptake, which was strongly
reduced in cells that had been pre-incubated for 30 min with the
antibody (952 nM; Figure 4C).
At this concentration, the antibody was significantly less
effective on all other connexin hemichannels of the pool we
tested (Figure 5), namely hCx30.2/31.3 (GJC3), hCx30.3 (GJB4),
hCx31(GIB3), hCx31.1 (GJB5), hCx37 (GJA4), hCx43 (GJA1),
hCx45 (GJC1). Figure 5B provides a quantitative summary
of these results in histogram form: residual hemichannel
conductance following antibody application was equal to 16.8%
for hCx26 (data from Xu et al., 2017), 16% for hCx32, 25%
for hCx30, 91% for hCx30.2/31.3, 82% for hCx30.3, 87% for
hCx31, 73% for hCx31.1, 73% for hCx37, 73% for hCx43
and 98% for hCx45.
Pannexin 1 is an alternative mediator of intercellular signaling
(Barbe et al., 2006; Dando and Roper, 2009; Hanstein et al.,
2013; Bravo et al., 2014; Beckel et al., 2015; Dong et al.,
2016) with a pharmacology profile that overlaps partially
that of connexin hemichannels (Dahl et al., 2013; Giaume
et al., 2013). In HeLa-Panx1-YFP cells, which express no
connexins (Yi et al., 2017), plasma membrane channels
composed of pannexin 1 were not affected by abEC1.1
(applied at 952 nM concentration, Figure 6A), but were
blocked by known non-specific pannexin inhibitors such as
probenecid, carbenoxolone (CBX), 4,4-Diisothiocyanatostilbene-
2,2-disulfonic acid (DIDS) and Fast Green FCF (Figures 6B,C).
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FIGURE 3 | Detailed representation of the predicted interaction of abEC1.1 with the different protomers composing a hCx26 hemichannel. Panels (A–D) show four
representative snapshots along the MD simulation highlighting the most important interactions; different protomers are represented according to the color code used
in Figure 2B. The antibody heavy chain (HC) and light chain (LC) are represented in red and cyan, respectively. Each protein is represented according to its realistic
volume occupation in space. Critical residues are shown with atomistic detail.
Altogether, these results indicate that abEC1.1 can discriminate
between pannexin 1 channels and hemichannels composed of
hCx26, hCx30 or hCx32.
Assay of Antibody in vitro Stability by
Size Exclusion Chromatography (SEC)
Aggregation of monoclonal antibodies into high molecular
weight species is an irreversible process that is notorious for
its detrimental effects on antibody efficiency and safety (Beck
et al., 2013). SEC is a widespread method for stability monitoring
due to its short run times and quantitative reproducibility
(Goyon et al., 2017). The peak-normalized chromatographic
profiles (absorbance at 405 nm vs. retention time) in Figure 7A
indicate abEC1.1 undergoes minimal or no aggregation for
up to 16 days at temperatures comprised between 4◦C and
37◦C. Some abEC1.1 aggregates become noticeable for samples
held at 42◦C for 16 days. Figure 7B shows representative
chromatographic profiles obtained from abEC1.1m, an antibody
with the scFv domain of abEC1.1 fused in frame to a mouse
Fc. A higher tendency to aggregate, signaled by the appearance
of multiple peaks for abEC1.1m held at 42◦C for 16 days, is
evident at these rather extreme conditions. Altogether, these
results confirm that abEC1.1 is a potential candidate protein
biopharmaceutical.
DISCUSSION
Anti-connexins Antibodies as Tools to
Interfere With Hemichannel Function
A few monoclonal or polyclonal antibodies that recognize
the extracellular domain of Cx43 have been generated (Meyer
et al., 1992; Hofer and Dermietzel, 1998; Siller-Jackson et al.,
2008; Baklaushev et al., 2009, 2011) and used in diverse
contexts to address biological questions regarding gap junction
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TABLE 1 | Sequence alignment of human connexin proteins in the regions where
hCx26 is presumed to bind abEC1.1.
Gene Name Protein name EC1 amino acids
54–58
EC2 amino acids
175–176
GJB2 hCx26 NTLQP PN
GJB6 hCx30 NTLQP PN
GJB1 hCx32 NTLQP PN
GJB4 hCx30.3 NTKQP PH
GJD3 hCx31.9 NTLQP PH
GJA8 hCx50 NTQQP PN
GJA3 hCx46 NTQQP PN
GJA10 hCx62 NTRQP PN
GJB5 hCx31.1 NTRQP PN
GJB3 hCx31 NTKQP PN
GJA9 hCx59 NTEQP PN
GJC2 hCx47 NTRQP PH
GJA1 hCx43 NTQQP PH
GJA5 hCx40 DTIQP PH
GJD4 hCx40.1 NTLQP TG
GJC1 hCx45 NTEQP PH
GJD2 hCx36 NTLQP IK
GJG3 hCx30.2 HTQQP LG
CJB7 hCx25 NSRQP PN
GJA4 hCx37 NTAQP PY
Residue Thr177 is part of the putative binding interface (see P3-EC2 in Table 2) but
contributes only with its main chain, therefore it was not included in this table.
assembly and hemichannel function [reviewed in Riquelme et al.
(2013)], as well as for the potential treatment of cancer and
inflammatory states (Jiang et al., 2018). Polyclonal “CELAb”
antibodies raised in rabbits against a peptide corresponding to
residues 42–53 in the EC1 region of hCx26 (VWGDEQADFVC),
or another peptide corresponding to residues 172–184 in EC2
(AWPCPNTVDCFVSR), were used to detect Cx26 hemichannels
in HeLa cells transfected with Cx26-eYFP, as well as to block
dye uptake promoted by low Ca2+ conditions in both HeLa cells
and CaCo-2/TC7 cells (Clair et al., 2008). The same antibodies
detected connexin hemichannels also at the endolymphatic
surface of the organ of Corti in mouse organotypic cochlear
cultures (Anselmi et al., 2008; Majumder et al., 2010). However,
to our knowledge, no translational follow-up has been developed
using CELAb antibodies.
Structural Determinants of
abEC1.1-Hemichannel Interaction
abEC1.1 is the first connexin-binding human-derived
monoclonal antibody that was selected from a vast phage display
library (Zhang et al., 2012) using a bait peptide corresponding
to residues 41-56 of EC1 in hCx26 (Qu et al., 2017). In the
following, we will refer to hemichannel interactions with one of
the two binding antibodies, keeping in mind that the pattern is
symmetrical for the second antibody. Prior work allowed us to
identify critical residues in the hemichannel-antibody binding
interface, namely EC1 residues Asn54, Thr55 and Leu56, and
antibody residues Tyr34, His55 and Trp104 (Xu et al., 2017).
TABLE 2 | Interaction probability of hCx26 residues with abEC1.1.
Hemichannel amino acid Interaction probability
P1-EC1
Asn54 82%
Thr55 56%
Leu56 85%
P1-EC2
Pro175 29%
P2-EC1
Cys53 10%
Asn54 92%
Thr55 82%
Leu56 100%
Gln57 78%
Pro58 31%
P2-EC2
Pro173 2%
Pro175 68%
Asn176 21%
Thr177 4%
Val178 2%
P3-EC1
Asn54 63%
Thr55 7%
Leu56 100%
Gln57 65%
Pro58 7%
P3-EC2
Trp172 12%
Pro173 7%
Pro175 43%
Asn176 56%
Thr177 68%
P4-EC1
Thr55 2%
Leu56 85%
Gln57 90%
Pro58 73%
P4-EC2
Pro175 14%
Asn176 5%
At blocking concentrations, two antibodies bind simultaneously a single hCx26
hemichannel (Xu et al., 2017). Different hCx26 protomers (P1 to P6) contribute
to the binding interface with different residues. One of the two antibodies binds
protomers P1-P2-P3-P4; the second binds protomers P4-P5-P6-P1 with an
identical interaction pattern. The interaction probability was computed as the time
fraction the listed hCx26 residues were in close contact with the antibody during
the MD simulation.
This work extends those results and suggests that two contiguous
N-T-L motifs in P2-P3 accommodate the CDR3 of the antibody
HC in a way that is reminiscent of hemichannel docking, owing
in particular to the hydrophobic interactions of P2 and P3
Leu56 with Phe102 and Trp104 of the antibody. Likewise, P1
and P2 N-T-L motifs bind both the scaffold and, partially, the
CDR2 loop of the antibody light chain, due to the formation
of hydrogen bonds between antibody Arg183 and P1 Ans54,
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FIGURE 4 | The abEC1.1 antibody inhibits hCx30 and hCx32 hemichannels in HeLa DH transfectants. (A,B) Whole cell currents elicited by voltage commands (top,
black trace) recorded from HeLa DH cells transiently transfected with hCx30 (A) or hCx32 (B) and perfused with an extracellular solution containing 0.2 mM Ca2+
concentration. Shown are mean values (thick traces) ± s.e.m. (thin traces) for at least n = 3 cells in each data set. Total hemichannel currents were measured before
(blue traces, control) and after (green traces) application of abEC1.1 by pressure at 952 nM for 15 min. Data were normalized to the mean value of the control
response evoked by application of the depolarization step. Top insets show normalized outward currents measured immediately after the voltage commands to +40
mV (A) or +60 mV (B). Asterisks indicate significance level between control condition and antibody application (∗∗P < 0.01; ∗∗∗P < 0.001, paired t-test). (C) Dye
uptake assays (see section “Materials and Methods”). Cells were bathed in a divalent-free extracellular medium (ECM) or ECM + 952 nM abEC1.1. Shown are
representative fluorescence images of the same field of view before (t0) and after 30 min of incubation with 2 mM Lucifer Yellow (t30). These experiments were
performed twice for each type of HeLa DH transfectants (Mock, hCx30, hCx32). Histogram shows mean values ± s.e.m. of the difference between t30 and t0
fluorescence intensity values measured in 50 cells for each condition (A.U., arbitrary units; ∗∗P < 0.01, ∗∗∗P < 0.001, Mann–Whitney U test). Scale bar = 20 µM.
and to the interaction of antibody Tyr178 and Thr183 with
Thr55 and Leu56 of P2. The conclusion based on this analysis
is that the EC1 loop apex in all six protomers contributes to
antibody binding (Figures 2, 3 and Tables 2, 3). Residues
Thr30, Ser32, Ser33 and Tyr34 in the CDR1 of the antibody
HC reside between the EC1 of P3 and P4 and occupy a more
external position relative to the center of the channel, so that
also Gln57 and Pro58 in EC1 and Pro175 in EC2 are involved
in the antibody-connexon interaction. Finally, the CDR2 of the
antibody HC interacts with P3 only through His55, which finds
Frontiers in Physiology | www.frontiersin.org 8 June 2019 | Volume 10 | Article 392
fphys-10-00392 June 7, 2019 Time: 18:30 # 9
Ziraldo et al. abEC1.1 Specifically Modulates Connexin Hemichannels
FIGURE 5 | Specificity of the abEC1.1 antibody for different connexin hemichannels expressed in HeLa DH cells. (A) Black traces at the top represent voltage
commands applied under patch clamp conditions in order to elicit whole cell currents. Shown are mean values (thick traces) ± s.e.m. (thin traces) of currents
recorded in control conditions (blue traces) and after (green traces) abEC1.1 application by pressure at 952 nM concentration from a glass micropipette for 15 min.
All data were normalized to the mean value of current elicited by the depolarization step to +40 mV. The effect of the antibody was tested on at least n = 3 cells, for
each different connexin isoform. HeLa DH transfectants were superfused into an extracellular solution with low calcium concentration (0.2 mM). Top insets show
normalized outward currents measured immediately after the voltage commands to +40 mV. Data revealed no statistical difference between control condition and
antibody application. (B) Histograms (mean ± s.e.m.) represent membrane conductance computed from data shown in panel (A) and normalized to current values
measured before antibody application. Asterisks indicate significance level (∗∗P < 0.01; ∗∗∗P < 0.001, ANOVA) for abEC1.1 effect on hemichannel currents
measured in the indicated HeLa DH transfectants, taking hCx26 hemichannel currents in the presence of the antibody as reference.
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FIGURE 6 | The abEC1.1 antibody does not affect human pannexin 1 (Panx1) hemichannel currents in HeLa-Panx1-YFP cells. Black traces at the top represent
voltage protocols applied under patch clamp conditions to elicit whole cell currents in HeLa cells expressing Panx1. (A) Whole cell currents recorded in response to
voltage steps from –80 to +120 mV before (control conditions) and after abEC1.1 antibody application at 952 nM for 15 min. (B) Inhibition of human Panx1 currents:
shown are measurements of whole cell currents recorded in response to voltage protocol application after inhibitory compounds were delivered by pressure for
2 min (CBX, 50 µM) or 4 min (DIDS, Probenecid, Fast Green FCF, 100 µM). Results in panels (A) and (B) are representative of 4 to 8 experiments for each condition.
(C) Histograms (mean ± s.e.m.) represent maximal outward and inward currents normalized to corresponding control values measured before antibody or pannexin
inhibitor application. Asterisks indicate significance level relative to Control (∗∗P < 0.01; ∗∗∗P < 0.001, ANOVA).
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FIGURE 7 | Peak-normalized SEC chromatographic profiles (absorbance vs. retention time) of antibodies maintained under different storage conditions.
(A) abEC1.1; (B) abEC1.1m; see section “Materials and Methods” and Refs. therein.
an equilibrium position between the apical part of EC1 (Asn54)
and EC2 (Pro175, Asn176 and the main chain of Thr177). Note
that, apart from the EC2 Asp179, all other EC1 and EC2 residues,
which are critical for hemichannel docking and formation
TABLE 3 | Interaction probability of abEC1.1 residues with the extracellular
domain of the hCx26 hemichannel.
Antibody
amino acid
Interaction
probability
Antibody
amino acid
Interaction
probability
HC Constant
Region
LC Constant
Region
Ser27 19% Tyr178 80%
Asn76 14% Thr182 98%
Ser77 5% Arg183 93%
Asn79 2% Ala184 58%
Thr185 85%
HC-CDR1 Gly186 68%
Gly28 29% Ile187 43%
Phe29 53% Pro188 63%
Thr30 100% Asp189 85%
Ser32 70%
Ser33 98% LC-CDR1
Tyr34 98% Ser160 5%
HC-CDR2 LC-CDR2
His55 73% Gly179 2%
Ser181 37%
HC-CDR3
Phe102 78%
Ser103 90%
Trp104 100%
Arg105 17%
The interaction probability was computed as the time fraction the listed abEC1.1
residues were in close contact with extracellular domain of the hCx26 hemichannel
during the MD simulation. HC, heavy chain; LC, light chain; CDR, complementarity
determining region.
of intercellular channels, mediate also hemichannel binding
to the antibody.
Together with sterical hindrance arguments, this analysis
provides a mechanistic cue for the observed strong reduction of
electrical conductance and dye uptake for hCx26 (Xu et al., 2017),
hCx30 and hCx32 hemichannels (this work), which have 100%
identical sequences in the predicted binding region (in hCx30 the
amino acid corresponding to Thr177 is a Leu, but the interaction
with the antibody is only mediated by the oxygen and nitrogen of
the main chain).
Summarizing, the pattern of interaction is remarkably rich
and the repeated N-T-L sequence binds different regions of the
antibody. A single amino acid difference in a limited group
of 8 protomer residues is sufficient to reduce significantly the
antibody effects on all other types of hemichannels tested.
Residues belonging to the hemichannel and the antibody which
contribute most to the interaction are shown in Tables 2
and 3, respectively.
Antibody Selection Based on Phage
Display Library Screening: Potential
and Caveats
The atomistic model presented here, validated by patch clamp
measurements, imply that it is possible to identify hemichannel
blocking antibodies which are specific at least for different
connexin subfamilies. However, our results also imply that
screening antibody libraries against a simple bait peptide does not
guarantee that the selected antibodies recognize the hemichannel
surface exposed to the solvent. Indeed, it is well known that
successful isolation of novel antibodies by phage display is
critically limited by the presentation of a correctly folded antigen.
The discovery of new and more selective antibodies capable of
interfering with connexin hemichannels will undoubtedly benefit
from improved methods targeting membrane proteins in their
native conformation and optimized for whole cell biopanning
(Jones et al., 2016, 2018).
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CONCLUDING REMARKS
Given that abEC1.1 is stable in vitro, we consider the results
presented here as potentially relevant for disorders caused by
augmented hemichannel activity of hCx26 (Stong et al., 2006;
Gerido et al., 2007; Lee et al., 2009; Mhaske et al., 2013; Sanchez
et al., 2014; Garcia et al., 2015), hCx30 (Essenfelder et al., 2004)
and hCx32 (Abrams et al., 2002; Liang et al., 2005), which
include Keratitis-ichthyosis-deafness syndrome (OMIM 148210),
Hystrix-like ichthyosis with deafness (OMIM 602540), Ectodermal
displasia 2, Clouston type (OMIM 129500), and Charcot-Marie-
Tooth disease, X-linked dominant, 1 (OMIM 302800). In vivo
experiments with relevant animal models will be key to test the
therapeutic potential of this antibody.
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